Actively Recruiting
Neoadjuvant Treatment For Locally Advanced Thymic Cancer
Led by Shanghai Pulmonary Hospital, Shanghai, China · Updated on 2026-05-08
25
Participants Needed
1
Research Sites
164 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aims of this study are to verify the feasibility, effectiveness, and safety of the combination of enrolizumab and radiotherapy for neoadjuvant treatment for locally advanced thymic carcinoma, and to provide recommendations for the establishment of unified evaluation criteria for the neoadjuvant therapy of thymic cancer by evaluating the pathological remission status of thymic cancer specimens after neoadjuvant treatment.
CONDITIONS
Official Title
Neoadjuvant Treatment For Locally Advanced Thymic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of thymic carcinoma by pathology
- Clinical stage III to IVA thymic carcinoma without myasthenia gravis, suitable for surgery
- Age 18 years or older and under 75 years at consent
- Able to understand and voluntarily sign informed consent
- No prior anti-thymic tumor treatments, including chemotherapy, radiotherapy, or immunotherapy (traditional Chinese medicine for anti-tumor allowed with 2-week washout)
- At least one measurable tumor lesion per RECIST V1.1
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Negative serum pregnancy test within 7 days before first treatment for women of childbearing potential
- Agree to use effective contraception from 7 days before first treatment until 24 weeks after treatment ends
- Adequate organ function within 7 days before first treatment, including bone marrow, coagulation, liver, kidney, and lung function suitable for surgery
You will not qualify if you...
- Diagnosis of thymic neuroendocrine tumor
- Major surgery within 28 days before treatment or not fully recovered
- Use of systemic corticosteroids (≥10 mg prednisone daily) or immunosuppressants for 7 days within 14 days before treatment, except for certain short-term or local uses
- Receipt of live vaccines within 28 days before treatment
- History or current interstitial lung disease requiring systemic steroids
- History or current autoimmune diseases excluding some stable or mild conditions
- Other malignancies within 5 years except certain cured or low-risk cancers
- Uncontrolled heart, kidney, gastrointestinal, infectious diseases or other complications
- History of allogeneic bone marrow or organ transplant
- Prior treatment with immune checkpoint inhibitors or anti-tumor vaccines
- History of severe allergic reactions to antibody drugs or asthma uncontrolled by treatment
- Pregnant or breastfeeding women
- Other conditions affecting safety or compliance, such as mental illness, recurrent large fluid accumulation, or cachexia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Actively Recruiting
Research Team
J
Juemin Yu
CONTACT
D
Deping Zhao, MD,PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here